²é¿´: 10964  |  »Ø¸´: 5

a070274011

гæ (³õÈëÎÄ̳)

[½»Á÷] Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ ÒÑÓÐ4È˲ÎÓë

1. 96 ¿×°åÑù±¾´¦Àí
1.1 ²Ù×÷Á÷³Ì
½ÓÖÖϸ°û£º3¡Á104 /¿× Ò©Îï´Ì¼¤ Ò»°ã×÷ÓÃ24 Сʱ£¬ÉÏ»ú
1.2 ·½·¨
ÔÚcellquest »·¾³Ï£¬ÀûÓÃcontrol ϸ°û±ê¶¨ÉÏÑùÌõ¼þ£¬²¢ÔÚÒÑÉèºÃµÄÎļþ
¼Ð(INS Îļþ¼°SET Îļþ)Ï£¬±£´æºÃÐèÒªµÄÉÏÑùÎļþ ¹Ø±Õcellqest Èí¼þ£¬
´ò¿ªMPM Èí¼þ ÔÚMPM Èí¼þϽøÐÐһϵÁÐÉ趨(Ê×ÏÈÔÚAutosample Ï£¬
½øÐÐSettingInitial ¼°FinalWashing ²Ù×÷£¬ÇåÏ´Õû¸ö¹Ü· ¹Ü·ÇåÏ´Íê±Ï½øÐÐ
ÉÏÑùÌõ¼þÉ趨(Ö÷ÒªÉ趨ÉÏÑùÌå»ý(Ò»°ã100ul)£¬»ìºÏÌå»ý(Ò»°ã100ul)£¬»ìºÏ´ÎÊý£¬
ÇåÏ´´ÎÊýµÈ£¬ÔÚAcquisition ²Ëµ¥ÏÂÉ趨current plate(ÏÖÔÚʹÓõİåºÅÊÇ353263)£¬
DateStorageFolder( ¼´Êý¾Ý´¢´æÎļþ¼Ð) £¬ AcquisitionDocument ¼°
InstrumentSettingsFile(ÉÏÑùÌõ¼þ´Ó±£´æºÃµÄINS ¼°SET ÎļþÖÐÑ¡¶¨) ÉÏÑù
Ìõ¼þÉ趨Íê±Ï£¬Ñ¡¶¨96 ¿×°åµÄÉÏÑù·¶Î§ ÔÚAcquisition ÏÂÑ¡ÔñAcquire,
ÉÏÑù ÉÏÑùÍê±Ï£¬Í˳öÉÏÑù°å£¬Ê¹ÓôÎ**ÄÆ¼°Ë®£¬ÇåÏ´¹Ü·(½«´Î**ÄÆ
¼°Ë®¼ÓÔÚ96 ¿×°åÉÏ£¬ÒÔÉÏÑùµÄ·½Ê½ÇåÏ´¹Ü·)
*ÐëÖª£ºÈç¹ûʹÓÃPBS ×÷ΪÉÏÑùÇÊÒº£¬ÉÏÑùÍê±Ïºó£¬»»ÓÃË®×÷ΪÇÊÒº£¬²¢·´¸´³å
Ï´¹Ü·£¬·ÀÖ¹PBS Ñνᾧ¶ÂÈû¹Ü·¡£
1.3 ×¢ÊÍ
1) ±ØÐèµÄcontrol£ºÓ¦×¼±¸Ò»¹Ü¶ÔÓÚ¼ì²âÖ¸±êΪÒõÐÔµÄϸ°û(ÀýÈ磺ÈôÒª¼ì²â
Jurkat-NF-KB-GFP ¾­Ò©Îï´Ì¼¤Ñù±¾£¬¾ÍÐèҪ׼±¸Ò»¹ÜJurkat ϸ°û(GFP ΪÒõ
ÐÔ))£¬ÓÃÓڱ궨»úÆ÷µÄÉÏÑùÌõ¼þ¡£Ï¸°ûÁ¿Îª1¡Á106 ¸ö/ml£¬1ml¡£
2) ÉÏ»úǰ£¬Ó¦¶ÔÑù±¾½øÐлìºÏ£¬ÒÔʹÑù±¾¾ùÒ»(×¢ÒâʹÓÃÅÅǹ´µ´ò£¬Îð²úÉúÆøÅÝ)¡£
3) ÒÔÉÏprotocol ½öÕë¶ÔÓÚÐü¸¡Ï¸°û¡£
4) Ò©Îï´Ì¼¤Å¨¶ÈÐèÏÈ×öÌݶȼì²â¡£
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
42
2. Cell Cycle Assay
³£ÓõÄʵÑéϸ°ûÖê°üÀ¨£º293(T)£¬MCF7£¬U2OS£¬Saos£¬Hela µÈ
ÒÔU2OS ϸ°ûΪÀý
2.1 ϸ°ûÅàÑø¼°ÆÌ°å
1) ϸ°ûÖê¼°²ÄÁÏ£º
a) ϸ°ûÖ꣺ U2OS ϸ°û
b) ÅàÑø»ù£º DMEM(10%FBS£¬GBICO)£¬DMEM(ÎÞѪÇå)
c) ÅàÑøÆ÷Ãó£º75cm2 ÅàÑøÆ¿,6cm ÅàÑøÃó
2) ϸ°ûÅàÑø¼°ÆÌ°å£º
a) ´«´ú£ºÓÃDMEM(10%FBS) ÅàÑø»ù½ÓÖÖU2OS ÖÁ75cm2 ÅàÑøÆ¿£¬Ï¸°û³¤
ÂúºóÆÌ°å²¢´«´ú¡£
×¢£ºÒ»°ãһƿϸ°û×ÜÊý¿ÉÒÔ´ïµ½1¡Á107 ¸ö
b) ÆÌ°å£º
ϸ°ûÏû»¯£º½«ÅàÑøºÃµÄU2OS ϸ°û£¬ÇãÈ¥ÅàÑø»ù£¬¼ÓÈë2ml 1¡ÁÒÈøÇáÇá
Ò¡»ÎÒÔ¸²¸ÇÕûƿϸ°û£¬37¡æÅàÑøÏä·ÅÖÃ2-3min£¬¹Û²ìϸ°û´Ó
Æ¿±ÚÉÏÍÑÂäÏÂÀ´(Ò²¿ÉÒÔÓÃÊÖÅÄ»÷Æ¿±Ú)£¬ÏÔ΢¾µÏ¹۲⵽ϸ°û
³Éµ¥¸ö£¬»òÊÇÖ»ÓÐ2-3 ¸öϸ°û¾ÛÍÅ£¬¼´¿ÉÒÔ¼ÓÈë5ml º¬ÓÐѪÇå
µÄDMEM(10%FBS)£¬ÖÕÖ¹ÒÈøµÄÏû»¯×÷Óá£
ϸ°û¼ÆÊý£ºÈç¹ûϸ°ûÃܶȽϴ󣬿ɰ´Ò»¶¨±¶ÊýÏ¡Êͺó¼ÆÊý¡£
ϸ°ûÃܶÈ(µ¥Î»£º¸ö/ml)=(4 ¸ö´ó·½¸ñµÄϸ°û×ÜÊý/4)¡Á104¡ÁÏ¡Êͱ¶Êý
ÆÌ°å£º 6cmÅàÑøÃó°´ÕÕÿ¿×6¡Á105 ¸öϸ°û(¼´1.5¡Á105/ml£¬4ml)
ϸ°û¼ÓÈëºó½«6cm ÅàÑøÃóÑØË®Æ½Ãæ×ÀÃæµÄ·½Ïòǰºó×óÓÒÀ´»Ø»Î¶¯
(ÊÖÊÆÒ»¶¨ÒªÇáÈá,·ÀÖ¹ÅàÑøÒºÆÃ³ö)£¬Ê¹Ï¸°ûÄܹ»¾ùÔÈ·Ö²¼£¬·ÅÖÃϸ
°ûÅàÑøÏäÉú³¤¡£
×¢£º¼ÆËãÆÌ°åÁ¿Ê±£¬Ó¦½«control °å£¬Ò©ÎïÑôÐÔ¶ÔÕÕ°å¼°ÖÊÁ£¶ÔÕհ忼ÂÇÔÚÄÚ¡£
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
43
2.2 תȾ
1£© ÊÔ¼Á¼°²ÄÁÏ£º
a) תȾÊÔ¼Á£ºLipofectamin 2000
b) ÖÊÁ££º¶ÔÕÕÖÊÁ££ºpEF-BOS
p21(ÑôÐÔ¶ÔÕÕ)
p16(ÑôÐÔ¶ÔÕÕ)
GFP-spectin
Ä¿µÄ»ùÒòÖÊÁ££¬¹¹½¨ÔÚpEF-FN ÔØÌåÉÏ
×¢£ºÈôÄ¿µÄ»ùÒòÔØÌå²»ÊÇpEF-FN,Ôò¶ÔÓ¦µÄ¿ÕÔØÌåÒªÏàÓ¦±ä»¯¡£
2£© תȾ£ºÏ¸°ûÃܶÈΪ50%-60%ʱ£¬½øÐÐתȾ
A£º0.3¦Ìg GFP-spectin+3¦Ìg interest gene+ serum free DMEM ÖÁÖÕÌå»ý500¦Ìl/
¿×¡£
B£º9.9¦ÌL lipofectamine 2000+490.1¦ÌL serum free DMEM Ìå»ýΪ500¦Ìl /¿×£¬ÊÒ
ηÅÖÃ5min
A£¬B ¶þÕß»ìºÏ£¬ÊÒηÅÖÃ20-30min ºó½«»ìºÏÒº»ºÂý¶ø¾ùÔȵļӵ½6cm °å
ϸ°ûÒºÖУ¬Ã¿°åΪ1000¦ÌL£¬ÇáÇáÒ¡»Î£¬Ê¹DNA ·Ö²¼¾ùÔÈ£¬×ªÈ¾5 Сʱºó£¬
»»ÖÃÅàÑøÒº(10%FBS+DMEM)¡£
2.3 ϸ°û·Ö°å
ϸ°û·Ö°å£º×ªÈ¾12-16 Сʱºó, ¸ù¾Ýϸ°ûÃܶȰ´1£º3 »ò1£º2 ·Ö°å£¬Ê¹·Ö
°åºóϸ°ûÃܶÈΪ30%×óÓÒ,37¡æ¼ÌÐøÅàÑø30h¡£
2.4 ¼ÓÒ©´Ì¼¤
³ýÁËÀûÓÃתȾÖÊÁ£×÷ΪÑôÐÔ¶ÔÕÕ£¬Ò²¿ÉʹÓÃÒ©Îï´¦Àíϸ°û×÷ΪÑôÐÔ¶ÔÕÕÑù±¾
ϸ°ûÆÌ°å24 Сʱºó£¬¼ÓÒ©´Ì¼¤£º
G1£¬S-arrest £ºL-mimosine: 0.5mM
5-fluorourcil: 10mM
G2/M arrest : nocodazole: 50ng/ml
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
44
¼ÓÒ©ºó£¬¼ÌÐøÅàÑø24 Сʱ
¸½×¢£º×÷ΪÑôÐÔ¶ÔÕյĻùÒò¼°Ò©ÎïµÄ¾ßÌåʹÓÃÇé¿ö¼û¸½±í1¡£
2.5 ϸ°ûÊÕ»ñ¼°´¦Àí
·Ö±ðÊÕ¼¯ÅàÑøÒº£¬ÔÚÿ¸ö6cm °åÖмÓÈë1ml ÒÈøÏû»¯(ϸ°ûÏû»¯µÄ·½·¨Í¬ÉÏ)¡£
Ïû»¯Íê±Ï£¬¼ÓÈëÒÑÊÕ¼¯µÄÅàÑøÒº(×¢ÒâÒ»Ò»¶ÔÓ¦£¬·ÀֹŪ´í)ÖкÍÒÈø¡£ÀëÐÄ(300g£¬
5min)ÊÕ¼¯Ï¸°û£¬ÆúÉÏÇ壬¼ÓÈë2-3ml 75%ÒÒ´¼(ϸ°ûÁ¿½Ï¶à£¬¿É×ÃÁ¿¶à¼Ó)£¬votex£¬
³ä·Ö»ìÔÈ£¬·ÅÈë-20oC ±ùÏ䣬±£´æ¡£
2.6 ÉÏ»úÑù±¾ÖƱ¸
´Ó-20oC È¡³öϸ°ûÑù±¾(ÖÁÉÙÒÑÔÚ-20oC ·ÅÖÃ4 Сʱ)£¬ÀëÐÄ(300g£¬5min)ÊÕ¼¯Ï¸
°û£¬ÆúÉÏÇå¡£1¡ÁPBS ÇåÏ´Á½±é£¬¼ÓÈë100ul 1¡ÁPBS£¬votex »ìÔÈ£¬¼ÓÈë10ulPI(ÖÕ
Ũ¶È100ug/ml)£¬10ulRnase(ÖÕŨ¶È50ug/ml)£¬ÖÃÓÚ37oC ˮԡ¹ø£¬±Ü¹â´¦Àí30min¡£
×¢£ºÏ¸°ûÁ¿½Ï¶àʱ£¬PI ¼°RNase Á¿Ó¦×ÃÁ¿Ôö¼Ó¡£
2.7 ÉÏ»ú
ÔÚcellquest »·¾³Ï£¬Ñ¡ÔñFL-1(GFP)¼°FL-3(PI)×÷ΪÑо¿¶ÔÏó£¬ÏÈÉÏcontrol
Ñù±¾±ê¶¨ÉÏÑùÌõ¼þ£¬½ø¶øÉÏÆäËûÑù±¾¡£
2.8 Ïà¹ØÊÔ¼ÁµÄÅäÖÆ
1£®1¡ÁPBS£º²ÉÓÃGIBCO 1¡Á10L D¡¯PBS(Cat.No21600-069)ÅäÖÆ¡£
2£®PI£ºÒÔˮΪÈܼÁ£¬Ä¸ÒºÅ¨¶ÈΪ1mg/ml£¬ÅäÖÆÍê±Ïºó£¬4oC ±Ü¹â±£´æ
3£®Rnase£ºÒÔˮΪÈܼÁ£¬Ä¸ÒºÅ¨¶ÈΪ0.5mg/ml£¬ÅäÖÆÍê±Ïºó£¬·Ö×°¶³´æÓÚ-20oC
4£®L-mimosine£º ÒÔÎÞѪÇåÅàÑøÒºÎªÈܼÁ£¬Ä¸ÒºÅ¨¶ÈΪ100mM£¬ÅäÖÆÍê±Ïºó£¬
4oC ±Ü¹â±£´æ
5£®5-fluorourcil£ºÒÔDMSO ΪÈܼÁ£¬Ä¸ÒºÅ¨¶ÈΪ549mM£¬ÅäÖÆÍê±Ïºó£¬4oC ±£
´æ
6£®Nocodazole£ºÒÔDMSO ΪÈܼÁ£¬Ä¸ÒºÅ¨¶ÈΪ5mg/ml£¬ÅäÖÆÍê±Ïºó£¬4oC ±£´æ
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
45
¸½±í1£ºÑôÐÔ¶ÔÕÕ»ùÒò¼°Ò©Îï
3.FACS analysis on Apoptosis
¿ÉÓÃÓÚµòÍö¼ì²âµÄϸ°û£¬¶àΪ¶Ôϸ°ûµòÍö½ÏΪÃô¸ÐµÄϸ°û£¬ÀýÈ磺MCF7, Hela
ÒÔHela ϸ°ûΪÀý
3.1 ϸ°ûÅàÑø¼°ÆÌ°å
1) ϸ°ûÖê¼°²ÄÁÏ£º
i. ϸ°ûÖ꣺ Hela ϸ°û
ii. ÅàÑø»ù£º DMEM(10%FBS GBICO)£¬DMEM(ÎÞѪÇå)
iii. ÅàÑøÆ÷Ãó£º75cm2 ÅàÑøÆ¿,6cm ÅàÑøÃó
2) ϸ°ûÅàÑø¼°ÆÌ°å£º
a) ´«´ú£ºÓÃDMEM(10%FBS) ÅàÑø»ù½ÓÖÖhela ϸ°ûÖÁ75cm2 ÅàÑøÆ¿£¬Ï¸°û
³¤ÂúºóÆÌ°å²¢´«´ú¡£
×¢£ºÒ»°ãһƿϸ°û×ÜÊý¿ÉÒÔ´ïµ½3¡Á107 ¸ö
b) ÆÌ°å£º
i.ϸ°ûÏû»¯£º½«ÅàÑøºÃµÄHela ϸ°û£¬ÇãÈ¥ÅàÑø»ù£¬¼ÓÈë2ml 1¡ÁÒÈøÇá
ÇáÒ¡»ÎÒÔ¸²¸ÇÕûƿϸ°û£¬37¡æÅàÑøÏä·ÅÖÃ2-3min£¬¹Û²ìϸ
°û´ÓÆ¿±ÚÉÏÍÑÂäÏÂÀ´(Ò²¿ÉÒÔÓÃÊÖÅÄ»÷Æ¿±Ú)£¬ÏÔ΢¾µÏ¹۲â
»ùÒò Ò©Îï
G0/G1 P21,P16 L-mimosine: 0.5mM
S 5-fluorourcil: 10mM
G2/M nocodazole: 50ng/ml
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
46
µ½Ï¸°û³Éµ¥¸ö£¬»òÊÇÖ»ÓÐ2-3 ¸öϸ°û¾ÛÍÅ£¬¼´¿ÉÒÔ¼ÓÈë5ml
º¬ÓÐѪÇåµÄDMEM(10%FBS)£¬ÖÕÖ¹ÒÈøµÄÏû»¯×÷Óá£
ii.ϸ°û¼ÆÊý£ºÈç¹ûϸ°ûÃܶȽϴ󣬿ɰ´Ò»¶¨±¶ÊýÏ¡Êͺó¼ÆÊý¡£
ϸ°ûÃܶÈ(µ¥Î»£º¸ö/ml)=(4 ¸ö´ó·½¸ñµÄϸ°û×ÜÊý/4)¡Á104¡ÁÏ¡Êͱ¶Êý
iii.ÆÌ°å£º 6cm ÅàÑøÃó°´ÕÕÿ¿×3¡Á105 ¸öϸ°û(¼´0.75¡Á105/ml£¬4ml)½ÓÖÖ£¬
ϸ°û¼ÓÈëºó½«6cm °åÑØË®Æ½Ãæ×ÀÃæµÄ·½Ïòǰºó×óÓÒÀ´»Ø»Î¶¯(ÊÖÊÆÒ»¶¨
ÒªÇáÈá,·ÀÖ¹ÅàÑøÒºÆÃ³ö)£¬Ê¹Ï¸°ûÄܹ»¾ùÔÈ·Ö²¼£¬·ÅÖÃϸ°ûÅàÑøÏäÉú³¤¡£
×¢£º¼ÆËãÆÌ°åÁ¿Ê±£¬Ó¦½«control °å£¬Ò©ÎïÑôÐÔ¶ÔÕÕ°å¼°ÖÊÁ£¶ÔÕհ忼ÂÇÔÚÄÚ¡£
3.2 תȾ
1)ÊÔ¼Á¼°²ÄÁÏ£º
תȾÊÔ¼Á£ºLipofectamin 2000
ÖÊÁ££º a:¶ÔÕÕÖÊÁ££ºpEF-BOS
RIP(ÑôÐÔ¶ÔÕÕ)
b:GFP-spectin
c:Ä¿µÄ»ùÒòÖÊÁ££¬¹¹½¨ÔÚpEF-FN ÔØÌåÉÏ
×¢£ºÈôÄ¿µÄ»ùÒòÔØÌå²»ÊÇpEF-FN,Ôò¶ÔÓ¦µÄ¿ÕÔØÌåÒªÏàÓ¦±ä»¯¡£
2)תȾ£ºÏ¸°ûÃܶÈΪ50%-60%ʱ£¬½øÐÐתȾ
A£º0.15¦Ìg GFP-spectin+3¦Ìg interest gene+ serum free DMEM ÖÁÖÕÌå»ý500¦Ìl/¿×¡£
B£º9.45¦ÌL lipofectamine 2000+490.55¦ÌL serum free DMEM Ìå»ýΪ500¦Ìl /¿×£¬ÊÒ
ηÅÖÃ5min
A£¬ B ¶þÕß»ìºÏ£¬ÊÒηÅÖÃ20-30min ºó½«»ìºÏÒº»ºÂý¶ø¾ùÔȵļӵ½6cm ÅàÑøÃó
ÖУ¬Ã¿¿×Ϊ1000¦ÌL£¬ÇáÇáÒ¡»Î£¬Ê¹DNA ·Ö²¼¾ùÔÈ£¬×ªÈ¾5 Сʱºó,»»ÖÃÅàÑø
Òº(10%FBS+DMEM)¡£¼ÌÐøÅàÑø
3.3 ϸ°ûÊÕ»ñ
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
47
תȾ24 Сʱºó£¬Ò»µ©¹Û²ìµ½¾­RIP תȾµÄϸ°ûÃ÷ÏÔËÀÍö£¬¼´¿ÉÊÕ»ñϸ°û¡£
ÿ°å·Ö±ðÊÕ¼¯ÅàÑøÒº£¬ÔÚÿ¸ö6cm °åÖмÓÈë1ml ÒÈø(ϸ°ûÏû»¯µÄ·½·¨Í¬ÉÏ)£¬
Ïû»¯Íê±Ï£¬¼ÓÈëÒÑÊÕ¼¯µÄÅàÑøÒº(×¢ÒâÒ»Ò»¶ÔÓ¦£¬·ÀֹŪ´í)ÖкÍÒÈø£¬ÀëÐÄ(300g£¬
5min)ÊÕ¼¯Ï¸°û¡£
3.4 ÉÏ»úÑù±¾ÖƱ¸
ÊÕ¼¯Ï¸°ûÒº(°üÀ¨ÉÏÇå) ͬʱ׼±¸56¡æË®Ô¡´¦Àíϸ°û
·Ö±ðȡһµã
ûÓÐתȾµÄϸ°û
×÷Ϊcontrol
¼°×ªÈ¾µÄϸ°û
×÷ΪGFP µ¥È¾Ñù±¾ PBS Ï´
ȾAnnexinV Ab-PE Ⱦ7-AAD
ÊÒαܹâ15min
PE-mouse IgG ÊÒαܹâȾɫ15min
1¨wbinding buffer Ï´Á½´Î
Ⱦ7-AAD£¬ÊÒαܹâ15min AnnexinV Ab-PE/ 7-AAD Ⱦɫ£¬ÊÒαܹâ15min
3.5 ÉÏ»ú
ÔÚcellquest »·¾³Ï£¬Ñ¡ÔñFL-1(GFP)£¬FL-2(PE)¼°FL-3(7-AAD)×÷ΪÑо¿¶Ô
Ïó£¬ÏÈÉÏcontrol Ñù±¾±ê¶¨µçѹ£¬ÓòÖµ£¬ÔÙÓõ¥È¾GFP µÄϸ°ûÑù±¾¼°Ë®Ô¡´¦Àíºó
µ¥È¾PE,7-AAD µÄÑù±¾£¬µ÷½Ú²¹³¥£¬×îÖÕÈ·Á¢ÉÏÑùÌõ¼þ£¬½ø¶øÉÏÆäËûÑù±¾¡£
×¢£ºA:ÓÃGFP µ¥È¾Ñù±¾ÒÔ¼°Ë®Ô¡´¦ÀíµÄµ¥±êAnnexin V-PE Ñù±¾µ÷½ÚFL1-H ¼°
FL2-H µÄ²¹³¥£»
B:ˮԡ´¦ÀíµÄµ¥±êAnnexin V-PE ÒÔ¼°Ë®Ô¡´¦ÀíµÄµ¥±ê7-AAD Ñù±¾µ÷½Ú
FL2-H ¼°FL3-H µÄ²¹³¥¡£
4. CD69 ¼ì²â
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
48
(»òÆäËûÀàËÆµÄÃâÒßÓ«¹â¼ì²â)
4.1 ϸ°ûÅàÑø
1)ϸ°ûÖê¼°²ÄÁÏ£º
ϸ°ûÖ꣺Jurkat-T ϸ°û»òJurkat ϸ°û
ÅàÑø»ù£ºRPMI 1640(10%FBS GBICO£»1%Ë«¿¹)£¬RPMI 1640(ÎÞѪÇå)
ÅàÑøÆ÷Ãó£º75cm2 ÅàÑøÆ¿;175cm2 ÅàÑøÆ¿;25 cm2 ÅàÑøÆ¿;96 ¿×ϸ°ûÅàÑø°å
2)Jurkat-T ϸ°ûµÄÅàÑø£º
Jurkat-T ϸ°ûΪÐü¸¡Ï¸°û£¬Ï¸°û»îÁ¦ºÃʱ£¬¾µ¼ì¶àΪ10 ¸ö×óÓÒϸ°û¾ÛÍÅ£¬
¼°ÉÙÁ¿ÓÎÀëµÄµ¥¸öϸ°û£¬Ï¸°ûÔ²¶øÍ¸ÁÁ¡£Ò»°ãÅàÑø°´ÃܶÈÀ´¼ÆË㣬ÆðʼÅàÑø
ÃܶȲ»ÒªµÍÓÚ1¡Á105 ¸ö/ml£¬24hr ºóϸ°ûÃܶȼ´¿É´ïµ½2¡Á105 ¸ö/ml£¬ÒÔ´ËÀàÍÆ
ÔÚµÚÎåÌìÉϼ´¿ÉÒÔ´ïµ½1.6¡Á106 ¸ö/ml£¬¸ù¾ÝÕâ¸öÀ´µ÷Õû½ÓÖÖÃܶȼ°´«´úÌìÊý¡£
×îºÃϸ°ûµÄÃܶȸ߲»Äܳ¬¹ý1.6¡Á106 ¸ö/ml¡£
ÀýÈ磬ÆðʼÅàÑøÃܶÈ2¡Á105 ¸ö/ml£¬Ìå»ý30 ml£¬ÔÚµÚÈýÌìʱ, ϸ°ûÃܶÈ
´ïµ½8¡Á105 ¸ö/ml£¬Ï¸°û×ÜÊý´ïµ½2.4¡Á107 ¸ö£¬ÒòΪ¼ì²âÒ»¸ö´ý¼ì»ùÒòµÄµç»÷
ËùÐèϸ°ûÊýÁ¿Îª1¡Á107 ¸ö£¬ËùÒÔ£¬´ËÅàÑøµÄϸ°ûÊýÖ»ÄÜ×ö2.4 ¸öÑùÆ·£¬Òò´Ë£¬
¸ù¾ÝʵÑéËùÐèÒª¼ì²âµÄÑùÆ·ÊýÄ¿À´µ÷ÕûÅàÑøÏ¸°ûµÄÌå»ý(Ïó175cm2 µÄÅàÑøÆ¿
¿ÉÒÔÅàÑø200-300ml ϸ°ûÐüÒº£¬Ï¸°û×ÜÊý¿ÉÒÔ´ïµ½16-24¡Á107£¬ÕâÑù¾Í¿ÉÒÔ×ö
16-24 ¸öÑùÆ·)¡£
4.2 µç»÷ת»¯
ϸ°û×ÜÊý´ïµ½¼ì²âÑùÆ·ËùÐèÔò¿ÉתȾ(ϸ°ûÃܶÈ×îºÃÔÚ1¡Á106/ml ×óÓÒ)¡£
תȾÓÃÆ·£ºµç»÷ÒÇ£¬400mm µç»÷±­
ÖÊÁ££º a:¶ÔÕÕÖÊÁ££ºNFAT ´Ì¼¤ÏµÍ³£ºnegative control:pEF-BOS
positive control: SYC plasmid
NFAT ÒÖÖÆÏµÍ³: negative control:pEF-BOS
positive control: SLIM plasmid
b: NFAT-luc report plasmid
c:Ä¿µÄ»ùÒòÖÊÁ££¬¹¹½¨ÔÚpEF-FN ÔØÌåÉÏ
ÊÔ¼Á£º ̨ÅÎÀ¶(0.4%)
1)½«Jurkat-T ϸ°ûתµ½50ml ÀëÐĹÜÖУ¬Ï¸°û¼ÆÊý(ϸ°ûÃܶÈ×îºÃÔÚ1¡Á106 ×óÓÒ)¡£
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
49
2)1000rpmÀëÐÄ£¬ÓÃÎÞѪÇåµÄRPMI1640 ÅàÑøÒºÊÕ¼¯Ï¸°û£¬µ÷ÕûŨ¶ÈΪ2.5¡Á107/mL,
ÿ¸öµç¼«±­ÖмÓÈë400¦Ìl ϸ°ûÒº(ϸ°û×ÜÊýΪ1¡Á107 ¸ö)¡£
3)ÒÀ´Î¼ÓÈë10¦Ìg NFAT-luc reporter gene ºÍ20ug interest gene(Ìå»ý¿ØÖÆÔÚ20¦Ìl ÒÔ
ÄÚ)£¬Ê¹ÖÊÁ£ºÍϸ°û»ìÔÈ(¾¡Á¿²»Òª²úÉúÆøÅÝ)¡£
4)µç»÷Ìõ¼þ250V£¬950¦ÌF¡£µç»÷ǰÇáÇᵯ»÷µç»÷±­£¬½«±­µ×µÄϸ°ûÖØÐüÆðÀ´£¬×¢
Òâ²»Òª²úÉúÆøÅÝ¡£µç»÷ʱ¹Û²ìÒ»ÏÂtime constant(ԼΪ24ms)¡£
5)µç»÷ÍêºóÁ¢¼´µ¯»÷µç»÷±­µÄ²à±Úʹϸ°û»ìÔÈ£¬ÊÒÎÂÏ·ÅÖÃ30min¡£
6)½«µç¼«±­ÖеÄϸ°û¼Óµ½10mL RPMI1640 ÅàÑøÒºÖÐ(º¬serum)24cm2 ÅàÑøÆ¿£¬Åà
Ñø40hr(¼´ÅàÑøµ½µÚÈýÌìÉÏÎç)¡£
4.3 ÆÌ°å£¬¼ÓÒ©
C305£º1¡Ã60 Ï¡ÊÍʹÓÃ
PMA: ´¢´æÅ¨¶ÈΪ0.5mg/ml£¬Ó¦ÓÃŨ¶ÈΪ50ng/ml(Ï¡ÊÍ10000 ±¶))
Ionomycin: ´¢´æÅ¨¶ÈΪ1mM£¬Ó¦ÓÃŨ¶ÈΪ1¦ÌM(Ï¡ÊÍ1000 ±¶))£»
1)½«×ªÈ¾ÅàÑø40hr ºóµÄϸ°ûתµ½15ml ÀëÐĹÜÖУ¬½øÐлîϸ°û¼ÆÊý(̨ÅÎÀ¶È¾É«)£¬
ÀëÐÄÊÕϸ°û£¬µ÷Õûϸ°ûŨ¶ÈΪ2¡Á106/ml¡£
2)ÔÚ96 ¿×°åÖУ¬Ã¿¿×¼Ó50¦ÌL ϸ°û(ϸ°ûÊýΪ1¡Á105)£¬Ã¿¸öÑùÆ·»¹ÊÇÒª×ö3 ¸ö¸´
¿×¡£NFAT ´Ì¼¤ÏµÍ³£¬NFAT ÒÖÖÆÏµÍ³¿ÉÒÔͬʱ½øÐУ¬Ç°ÕßÎÞÐè¼ÓÒ©´Ì¼¤£¬ºó
ÕßÐèÒª×öC305 ¿¹Ìå´Ì¼¤ºÍPMA+ Ionomycin ´Ì¼¤£¬Òò´Ë£¬Ò»¸öÑùÆ·ÐèÒª×ö9
¸ö¸´¿×¡£°´Ë³ÐòÔÚ96 ¿×°åÖмÓÈëϸ°û£¬²¢ÏàÓ¦×öºÃ±ê¼Ç¡£
3) ¶ÔÓÚNFAT ´Ì¼¤ÏµÍ³£¬Ö±½ÓÔÚÿ¿×Öв¹¼Ó50¦Ìl ÐÂÏÊÅàÑø»ù£¬Ê¹ÖÕÌå»ýΪ100¦Ìl£»
¶ÔÓÚNFAT ÒÖÖÆÏµÍ³·Ö±ð¼ÓÈë50¦ÌL C305(anti-TCR, 60 ±¶Ï¡ÊÍ)£»»ò50¦Ìl
PMA(50ng/mL)+Ionomycin(1¦ÌM)£¬´Ì¼¤8-12 Сʱ¡£
4.4 ϸ°ûÊÕ»ñ¼°´¦Àí
½«´Ì¼¤8-12 СʱºóµÄϸ°ûÈ¡³ö£¬ÀëÐÄÊÕ¼¯Ï¸°û
4.5 Ñù±¾ÖƱ¸
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
50
A:CD69 ¼ä±ê·¨
Cells harvested
1 ¡Á PBS ÇåÏ´Á½±é
Cells were suspended in 1ml 1¡Ábinding buffer (1% BSA)
(cell Ũ¶ÈÔ¼1¡Á106/ml)
È¡ÆäÖеÄ100¦Ìl
5¦Ìl pure-Mouse IgG1 5¦Ìl Mouse anti-human CD69 (»òÆäËüÒ»¿¹)
(·ÇÌØÒìÐÔȾɫ)
4oC »ò±ùÉÏ·ÅÖ㬠30min
1¡Ábinding buffer (1% BSA) ÇåÏ´Á½±é(ÿ´Î4ml)
5¦Ìl PE goat anti-mouse IgG ¼° 5¦Ìl 7-AAD
4oC »ò±ùÉÏ£¬±Ü¹â·ÅÖÃ15min
1¡ÁPBS ÇåÏ´Á½±é(ÿ´Î2ml)
ÉÏ»ú
B:CD69 ¼ì²âÖ±±ê·¨
²Ù×÷²½Öè»ù±¾Í¬¼ä±ê·¨£¬Ö»ÊÇ×÷·ÇÌØÒâÐÔ¶ÔÕÕµÄÑù±¾£¬Ö±½ÓÓÃMouse
anti-human IgG-pe Ö±½Ó±ê¼Ç
4.6 ÉÏ»ú
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
51
ÔÚcellquest »·¾³Ï£¬Ñ¡ÔñFL-1(GFP)£¬FL-2(PE)¼°FL-3(7-AAD)×÷ΪÑо¿¶Ô
Ïó£¬ÏÈÉÏcontrol Ñù±¾±ê¶¨µçѹ£¬ãÐÖµ£¬²¢µ÷½Ú²¹³¥£¬×îÖÕÈ·Á¢ÉÏÑùÌõ¼þ£¬½ø¶ø
ÉÏÆäËûÑù±¾¡£
4.7 ¼¸ÖÖÒ©ÎïµÄ´¢´æÅ¨¶ÈºÍÓ¦ÓÃŨ¶È
TNF 1¡Á106U/Æ¿ 1mg=4¡Á107U, 1¡Á106U=25¦Ìg ÈÜÓÚ12.5mL PBS ÖУ¬Å¨¶ÈΪ
2¦Ìg/mL¡£
´¢´æÅ¨¶È£º2¦Ìg/mL
Ó¦ÓÃŨ¶È£º20ng/mL(Ï¡ÊÍ100 ±¶)
C305 60 ±¶Ï¡ÊÍʹÓá£
PMA and Ionomycin(dissolved in DMSO)
PMA:1 Ö§1mg ÈÜÓÚ2ml DMSO ¼´0.5mg/mL(´¢´æÓÚ-80¡ãC)
´¢´æÅ¨¶È£º0.5mg/ml
Ó¦ÓÃŨ¶È£º50ng/ml(Ï¡ÊÍ10000 ±¶)
Ionomycin: 1mg/747.1(MW)=1.33¡Á10-3mmol ÈÜÓÚ1.33ml,Ũ¶ÈΪ1mM¡£(´¢´æÓë
-80¡ãC)
´¢´æÅ¨¶È£º1mM
Ó¦ÓÃŨ¶È£º1¦ÌM(Ï¡ÊÍ1000 ±¶)
5. ϸ°û·ÖÑ¡
5.1 ·Öѡϸ°ûÑù±¾´¦Àí
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
52
Ìù±Úϸ°ûÅàÑø£ºÒ»¸öϸ°ûÑù±¾ Ðü¸¡Ï¸°ûÅàÑø£ºÒ»¸öϸ°ûÑù±¾
ÖÁÉÙÐèÒªÒ»¸ö10cm ϸ°û°å ϸ°û×ÜÊýÓ¦´óÓÚ1¡Á107
(ϸ°û×ÜÊý´óÓÚ1¡Á107 )
ÊÕ¼¯Ï¸°û
È¥³ýÅàÑøÒº
ÒÈøÏû»¯(Ò»°ã¼ÓÈë2ml ÒÈø£¬
37 oC ³ä·ÖÏû»¯£¬´óÔ¼3 ·ÖÖÓ,
Ïû»¯ÖÁϸ°ûÇáÅÄÍѱÚ)
¼ÓÈë5ml ÅàÑøÒºÖкͣ¬³ä·Ö
·Öɢϸ°û(¾¡Á¿Ê¹Ö®³Êµ¥
ϸ°ûÐüÒº,¿Éͨ¹ýÏÔ΢¾µ¹Û²ìÅжÏ)
È¡100ul ϸ°ûÉÏ»ú£¬²â¶¨×ªÈ¾Ð§ÂÊ£¬Ê£Óàϸ°û¼ÇÊý£¬ÀëÐÄ
¸ù¾ÝתȾЧÂÊ£¬·Öѡģʽ(Ò»°ãÑ¡ÓÃexclusion ģʽ)£¬µ÷½Úϸ°ûŨ¶È£¬´ïµ½
ÉÏÑùËÙÂÊ1000-3000 ¸ö/Ã룬ĿµÄϸ°û300 ¸ö/Ãë(ϸ°ûŨ¶È(¸ö/ul)=300/Ä¿µÄ
ϸ°û°Ù·ÖÂÊ)
ÉÏ»ú£¬·ÖÑ¡
·ÖÑ¡ºóϸ°û£¬1500 ת/Ã룬5min,ÀëÐÄÊÕ¼¯Ï¸°û
1) ÈôËùÒª·ÖÑ¡µÄÊÇÐü¸¡Ï¸°û£¬ÒªÇóϸ°û×ÜÊý´óÓÚ1¡Á107£¬Ö±½ÓÊÕ¼¯Ï¸°ûÒº
2) ±ØÐèµÄcontrol£º¾ÙÀý˵Ã÷£¬Èç¹ûÐèҪɸѡµÄÊÇGFP ÑôÐÔµÄϸ°û£¬±ØÐëÌṩû
ÓÐתȾµÄͬÖÖϸ°û¡£
3) Èç¹û·ÖÑ¡ºóµÄϸ°û»¹ÐèÒª¼ÌÐøÅàÑø£¬ÐèÒªÔ¤ÏÈÓÃÎÞ¾úµÄ4%BSA °üÂñÊÕ¼¯¹Ü
(ÔÚÎÞ¾úÊÕ¼¯¹ÜÖУ¬¼ÓÂú4%BSA £¬²¢·ÅÖÃÓÚ4¡æÖÁÉÙ1 Сʱ£¬Ê¹ÓÃǰµ¹³ý°ü
ÂñÒº)¡£
4) Èç¹û·ÖÑ¡ºóµÄϸ°û»¹ÐèÒª¼ÌÐøÅàÑø£¬ËùÓÐÓõ½µÄÊÔ¼Á£¬°üÀ¨ÇÊÒº£¬¶¼±ØÐëÎÞ
¾ú´¦Àí£»ÔÚ·Öѡǰ¼°·ÖÑ¡¹ý³ÌÖУ¬±ØÐë½øÐÐÑϸñÎÞ¾ú²Ù×÷£¬»úÆ÷ÐèÒª¾­¹ý¾Æ
¾«³åÏ´£¬ÎÞ¾úPBS ³åÏ´µÄ¹ý³Ì¡£
5.2 ·Öѡϸ°ûµÄÉÏ»ú²Ù×÷³ÌÐò
5.2.1 ÉÏ»ú·Öѡǰ׼±¸
µÚÆßÕ Á÷ʽϸ°û·ÖÎö·ÖÑ¡Êõ
53
1)ÎÞ¾ú·ÖÑ¡
·ÖѡǰҹFACS ÒÇÆ÷¼äÐè×ÏÍâÕÕÉä¹ýÒ¹£¬ÊÕ¼¯¹ÜÔ¤ÏÈÓÃ4%BSA °üÂñ(4
¡æÖÁÉÙ1 Сʱ) ·Öѡǰ³åÏ´»úÆ÷³ÌÐò£º1. ½«ÉÏÑù¹Ü»»³É75%¾Æ¾«£¬ÇÊÒº
ͰÖл»³É3L 75%¾Æ¾«³åÏ´£¬ÖÁ3L ¾Æ¾«ÍêÈ«ÅÜÍꣻ 2. µ¹È¥ÇÊҺͰÖвÐÓàµÄ¾Æ¾«£¬
ÓÃÎÞ¾úPBS ³åÏ´ÇÊҺͰʹ¾Æ¾«³¹µ×È¥³ý£¬¼ÓÎÞ¾úPBS ÖÁÇÊҺͰÂú£¬Í¬Ê±ÉÏÑù¹Ü
Öл»³ÉÎÞ¾úPBS£¬³åÏ´£¬Ê¹Ã¿¸öÊÕ¼¯¹ÜÊÕ¼¯ÒºÌåÔ¼20ml ×óÓÒ,¼´¿ÉÉÏ»ú·ÖÑ¡¡£
2)·ÇÎÞ¾ú·ÖÑ¡
Èç¹û²»ÐèÒªÎÞ¾ú·ÖÑ¡£¬¿É½öÓÃÉÙÁ¿¾Æ¾«³åÏ´£¬ÔÙÓÃPBS ³åÏ´ÖÁÿ¹ÜÊÕ¼¯Ô¼
20ml ºó¼´¿ÉÉÏ»ú·ÖÑ¡¡£
5.2.2 ÉÏ»ú·ÖÑ¡²½Öè
´ò¿ªcellquest Èí¼þ£¬ÏÈÉÏcontrol Ñù±¾£¬È·¶¨Ï¸°û»ñÈ¡Ìõ¼þ£¬²¢»®¶¨ÐèÒª»ñ
È¡µÄϸ°û·¶Î§£»ÔÚAcquire menu ²Ëµ¥Ï£¬Ñ¡ÔñSortSetup£¬²¢É趨SortSetup ϵÄ
һϵÁвÎÊý£¬É趨Íê±Ï£¬Acquire,ÉÏÑù·ÖÑ¡¡£
×¢£ºSortSetup ÏÂÖ÷ÒªµÄ²ÎÊýÉ趨ÈçÏ£º
SortGate Ñ¡Ôñ·ÖÑ¡ÃÅ£¬SortCount Ñ¡Ôñ0(Á¬Ðø·ÖÑ¡)£¬
SortMode Ñ¡Ôñ·Öѡģʽ(Ò»°ãʹÓÃexclusion)
*ÐëÖª£º·ÖÑ¡Íê±Ïºó£¬ÓÃË®³åÏ´£¬Ê¹Ã¿¸öÊÕ¼¯¹ÜÊÕ¼¯ÒºÌåÔ¼20ml ×óÓÒºó¿ÉÍ£Ö¹(·À
Ö¹·ÖÑ¡¹ÜµÀÖÐÐγÉÑνᾧ)¡£¼Ì¶øÓ󣹿³åÏ´·½·¨³åÏ´ÉÏÑù¹Ü¡£
5.3 Ïà¹ØÊÔ¼ÁµÄÅäÖÆ
1£®4%BSA ÈÜÒº:ʹÓÃ1¡ÁPBS ×÷ΪÈܼÁ,ÿ100ml 1¡ÁPBS ÖмÓÈë4gBSA,³ä·ÖÈÜ
½â.
2£®1¡ÁPBS ÈÜÒº:²ÉÓÃGIBCO 1¡Á10L D¡¯PBS(Cat.No21600-069)ÅäÖÆ¡£
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

ʵÑéÖеIJßÂÔ

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
2Â¥2012-07-02 20:55:19
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
3Â¥2012-07-03 11:21:16
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

exon2002

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Äܸø¸ö²Î¿¼ÎÄÏ׵ijö´¦Âð£¿ÓÃÁËÒ²ºÃÓиö²Î¿¼¡£
4Â¥2012-07-04 08:13:38
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

a070274011

гæ (³õÈëÎÄ̳)

ÒýÓûØÌû:
4Â¥: Originally posted by exon2002 at 2012-07-04 08:13:38
Äܸø¸ö²Î¿¼ÎÄÏ׵ijö´¦Âð£¿ÓÃÁËÒ²ºÃÓиö²Î¿¼¡£

àÅ¡£¡¢Ï´η¢Ìû»á×¢ÒâÕâµã¡£Ð»Ð»ÄãµÄÌáÐÑ
5Â¥2012-07-05 09:49:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

253524281

гæ (³õÈëÎÄ̳)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
±¾ÌûÄÚÈݱ»ÆÁ±Î

6Â¥2014-05-30 12:01:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ a070274011 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Çóµ÷¼Á£¬×Ü·Ö315£¬¿¼µÄÉúÎïÒ½Ò©£¬Ò»Ö¾Ô¸ºþÄÏʦ·¶´óѧ¡£µ÷¼Áµ½ÈκÎרҵ¶¼¿ÉÒÔ +3 С¶¡Ïë½ø²½ 2026-03-11 3/150 2026-03-17 11:13 by ³öÃÅ´ò½´ÓÍÊÇÃÛÖ
[¿¼ÑÐ] 332Çóµ÷¼Á +5 Zz°æ 2026-03-13 5/250 2026-03-17 11:01 by JineShine
[˶²©¼ÒÔ°] ÉîÛÚ´óѧ˶ʿÕÐÉú£¨2026Ç´«¸ÐÆ÷·½Ïò£¬½ö¼ȡµÚÒ»Ö¾Ô¸£© +4 xujiaoszu 2026-03-11 9/450 2026-03-17 10:29 by xujiaoszu
[¿¼ÑÐ] 268Çóµ÷¼Á +6 Ò»¶¨ÓÐѧÉÏ- 2026-03-14 7/350 2026-03-17 10:14 by Sammy2
[¿¼ÑÐ] »¯Ñ§¹¤³Ì321·ÖÇóµ÷¼Á +10 ´óÃ×·¹£¡ 2026-03-15 13/650 2026-03-17 06:57 by laoshidan
[¿¼ÑÐ] [µ¼Ê¦ÍƼö]Î÷ÄϿƼ¼´óѧ¹ú·À/²ÄÁϵ¼Ê¦ÍƼö +3 ¼â½ÇСºÉ 2026-03-16 6/300 2026-03-16 23:21 by ¼â½ÇСºÉ
[¿¼ÑÐ] 321Çóµ÷¼Á +5 ´óÃ×·¹£¡ 2026-03-15 5/250 2026-03-16 16:33 by houyaoxu
[¿¼ÑÐ] 331Çóµ÷¼Á£¨0703Óлú»¯Ñ§ +5 ZY-05 2026-03-13 6/300 2026-03-14 10:51 by Jy?
[¿¼ÑÐ] 330Çóµ÷¼Á +3 ?½´¸øµ÷¼Á¹òÁË 2026-03-13 3/150 2026-03-14 10:13 by JourneyLucky
[¿¼ÑÐ] 311Çóµ÷¼Á +5 Å£ÈéÌǵĿ¨¿¨ 2026-03-10 5/250 2026-03-14 00:05 by JourneyLucky
[¿¼ÑÐ] ²ÄÁϹ¤³Ì,326·Ö£¬Çóµ÷¼Á +6 KRSLSR 2026-03-10 6/300 2026-03-13 23:47 by JourneyLucky
[¿¼ÑÐ] 337Ò»Ö¾Ô¸»ªÄÏÀí¹¤0805²ÄÁÏÇóµ÷¼Á +7 mysdl 2026-03-11 9/450 2026-03-13 22:43 by JourneyLucky
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤Çóµ÷¼ÁÒ»Ö¾Ô¸ 985 ×Ü·Ö 295 +8 dream¡­¡­ 2026-03-12 8/400 2026-03-13 22:17 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 308Çóµ÷¼Á +5 ÊÇLupa°¡ 2026-03-11 5/250 2026-03-13 22:13 by JourneyLucky
[¿¼ÑÐ] ²ÄÁϹ¤³Ìµ÷¼Á +9 ßäßä¿Õ¿Õ 2026-03-12 9/450 2026-03-13 22:05 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤085600µ÷¼ÁÇóÀÏʦÊÕÁô +9 jiaanl 2026-03-11 9/450 2026-03-13 20:22 by JourneyLucky
[¿¼ÑÐ] ²ÄÁϹ¤³Ìµ÷¼Á +4 ßäßä¿Õ¿Õ 2026-03-11 4/200 2026-03-13 19:57 by JourneyLucky
[¿¼ÑÐ] 0856»¯¹¤Ô­Àí +6 z2839474511 2026-03-10 6/300 2026-03-13 10:41 by houyaoxu
[¿¼ÑÐ] 270Çóµ÷¼Á 085600²ÄÁÏÓ뻯¹¤×¨Ë¶ +3 YXCT 2026-03-11 3/150 2026-03-13 10:13 by houyaoxu
[¿¼²©] 26¶Á²© +4 Rui135246 2026-03-12 10/500 2026-03-13 07:15 by gaobiao
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û